背景:内脏脂肪积累和肥胖诱导的慢性炎症已被认为是多种疾病状态的早期标志物,尤其是女性。然而,脂肪分布对α1-酸性糖蛋白(AGP)的潜在影响,炎症的标志,尚不清楚。这项研究是为了调查肥胖之间的关系,脂肪分布,AGP水平。
方法:使用2015年至2018年通过国家健康和营养检查调查招募的成年女性的血液样本进行了横断面观察性研究。使用Tina-quantα-1-酸性糖蛋白Gen.2测定法测量血清AGP水平。根据从双能X射线吸收法评估获得的脂肪分布数据,体重指数(BMI),总脂肪百分比(TPF),安卓率脂肪(APF),gynoid脂肪百分比(GPF),安卓脂肪/雌核脂肪比率(AGR),内脏脂肪百分比(VPF),皮下脂肪百分比(SPF),内脏脂肪/皮下脂肪比(VSR)用作因变量.为了研究脂肪分布和AGP之间的联系,采用多元线性回归分析。此外,还进行了敏感性分析.
结果:本研究包括2,295名参与者。在调整协变量后,BMI,TPF,APF,GPF,VPF,和SPF与AGP水平呈正相关(BMI:β=23.6595CI:20.90-26.40;TPF:β=25.91CI:23.02-28.80;APF:β=25.2195CI:22.49-27.93;GPF:β=19.6595CI:16.96-22.34;VPF:β=12.4995CI:9.08-15.90;SPF:12.95.35β=5.89.95上述指标均与AGP呈正剂量-反应关系。就脂肪分布而言,AGR和VSR均与AGP呈正相关(趋势P<0.0001).特别是,当与AGR的三分体1中的个体相比时,三元组2和3的参与者有13.42mg/dL(95%CI10.66-16.18)和21.14mg/dL(95%CI18.16-24.12)更高的AGP水平,分别。与最低三分位数的参与者相比,VSR最高三分位数的参与者更有可能表现出AGP增加9.35mg/dL(95%CI6.11-12.59)。
结论:总体而言,这项研究揭示了女性脂肪比例/分布与AGP水平呈正剂量依赖性关系.这些发现表明,医生可以将异常的血清AGP和肥胖联系起来,并及时进行干预。
BACKGROUND: Visceral fat accumulation and obesity-induced chronic inflammation have been proposed as early markers for multiple disease states, especially in women. Nevertheless, the potential impact of fat distribution on α1-acid glycoprotein(AGP), a marker of inflammation, remains unclear. This research was conducted to investigate the relationships among obesity, fat distribution, and AGP levels.
METHODS: A cross-sectional observational study was performed using blood samples from adult females recruited through the National Health and Nutrition Examination Survey from 2015 to 2018. Serum levels of AGP were measured using the Tina-quant α-1-Acid Glycoprotein Gen.2 assay. Based on the fat distribution data obtained from dual-energy X-ray absorptiometry assessments, body mass index (BMI), total percent fat (TPF), android percent fat (APF), gynoid percent fat (GPF), android fat/gynoid fat ratio (AGR), visceral percent fat (VPF), subcutaneous percent fat (SPF), visceral fat/subcutaneous fat ratio (VSR) were used as dependent variables. To investigate the link between fat distribution and AGP, multivariate linear regression analysis was utilized. Furthermore, a sensitivity analysis was also performed.
RESULTS: The present study included 2,295 participants. After adjusting for covariates, BMI, TPF, APF, GPF, VPF, and SPF were found to be positively correlated with AGP levels (BMI: β = 23.65 95%CI:20.90-26.40; TPF: β = 25.91 95%CI:23.02-28.80; APF: β = 25.21 95%CI:22.49-27.93; GPF: β = 19.65 95%CI:16.96-22.34; VPF: β = 12.49 95%CI:9.08-15.90; SPF: β = 5.69, 95%CI:2.89-8.49; AGR: β = 21.14 95%CI:18.16-24.12; VSR: β = 9.35 95%CI:6.11-12.59, all P < 0.0001). All the above indicators exhibited a positive dose-response relationship with AGP. In terms of fat distribution, both AGR and VSR showed positive associations with AGP (P for trend < 0.0001). In particular, when compared to individuals in tertile 1 of AGR, participants in tertiles 2 and 3 had 13.42 mg/dL (95% CI 10.66-16.18) and 21.14 mg/dL (95% CI 18.16-24.12) higher AGP levels, respectively. Participants in the highest tertile of VSR were more likely to exhibit a 9.35 mg/dL increase in AGP compared to those in the lowest tertile (95% CI 6.11-12.59).
CONCLUSIONS: Overall, this study revealed a positive dose-dependent relationship between fat proportion/distribution and AGP levels in women. These findings suggest that physicians can associate abnormal serum AGP and obesity with allow timely interventions.